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Abstract
Personalized care, which includes personalized medicine, personalized nutrition, and 
even personalized exercise, is a useful and a more effective method for the treatment 
and control of lifestyle diseases such as type 2 diabetes and cardiovascular diseases. The 
relationship between nutrients, diet and gene expression (commonly called as nutritional 
genomics or nutrigenomics) and precision or personalized medicine have received con-
siderable attention of researchers, clinicians, drug developers, practitioners of traditional 
system of medicine, and regulatory agencies over the years. Many, if not all, of the com-
mon human debilitating conditions including cancer, obesity, cardiovascular diseases 
and diabetes are related directly or indirectly to an individual’s nutritional status and 
its genetic make up. Understanding the interplay between diet and genes may help 
provide direction upon which personalized therapy can be used for the treatment and 
management of these catastrophic life-threatening conditions, including strategies for 
their prevention. In this era of human healthcare where the diagnosis of the disease and 
treatment of the patient are perceived to be patient-tailored, due to the differences in the 
genetic make-up of individuals and their lifestyle, personalized human healthcare could 
be the most effective method for the treatment and prevention of debilitating diseases 
with a high morbidity and mortality. This chapter provides an insight into the potential 
of individualized care in life-threatening complications.
Keywords: individualized care, precision medicine, lifestyle diseases, chronic 
inflammatory diseases
1. Introduction
Personalized or individualized care, which includes personalized medicine, as well as person-
alized nutrition and even personalized exercise, is an individual (patient)-centric, integrative, 
and holistic approach for the treatment and management of lifestyle diseases. Personalized 
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care, a term often used interchangeably with precision medicine (an essential piece of personal-
ized care which specifically refers to the medical treatment of the patient) is a more comprehen-
sive term (than personalized or precision medicine) that represents an overarching philosophy 
for patient care, taking the advantage of personalized medicine and pharmacogenomics, as 
well as personalized nutrition and exercise. Personalized medicine, as defined by Schleidgen 
et al. [1] as an emerging area of medical care seeking to improve stratification and timing of 
healthcare by utilizing biological information and biomarkers on the level of molecular disease 
pathways, genetics, proteomics, as well as metabolomics, is an essential piece of personalized 
care. The key issue of personalized or individualized medicine remains how a targeted therapy 
can be used to tackle rapidly increasing chronic health burden by maximizing therapeutic effi-
cacy and minimizing drug toxicity risks for an individual. Since the completion of the human 
genome project in the year 2000, the field has continued to evolve over the years especially 
from pharmacogenetics to pharmacogenomics so as to effectively monitor the multigenic effect 
on drug response [2]. Realization of the limitation of pharmacogenetics leads to the emergence 
of pharmacogenomics, which determines how genes affect a person’s response to drugs. This 
has opened up avenues for individualized identification of genetic variants using wide genome 
approaches through the use of latest and most recent methods, thus providing ways for deter-
mining molecular targets with the help of available DNA-based diagnostic screening tools [3].
A growing body of evidence has shown that chronic human diseases and conditions such as 
type 2 diabetes (T2D), cardiovascular diseases (CVD), atherosclerosis, obesity, and metabolic 
syndrome are associated with unhealthy lifestyle, which includes bad eating habits, physi-
cal inactivity, smoking, and exposure to stress [4]. A lifestyle modification with personalized 
nutrition and personalized physical activity is believed to play a central role in the prevention, 
management, and treatment of these life-threatening conditions [5]. Currently over 2500 genetic 
tests are available for the detection of diseases [6]. Ongoing efforts are being made to determine 
genetic risk of individuals to some of these diet-related conditions, like T2D and obesity, through 
available testing and screening methods so as to minimize the public health burden [7, 8]. Newer 
methods involving nanodiagnostic tools such as the DNA-based bionanosensors have recently 
emerged and are presumed to be safe and cost-effective with high specificity for early detection 
of the disease [9]. There is a vital need to educate the patients by the physicians and healthcare 
workers including the dietitians on the benefits of a well-balanced diet since failure to meet the 
nutritional requirements results in an array of conditions that occur due to the deficiency of 
certain nutrients. For example, the deficiencies of vitamins and minerals such as zinc, selenium, 
magnesium, chromium, and iron deficiencies have been reported in conditions like diabetes [10] 
and cystic fibrosis [11], especially among children. More recently, boron is getting recognition as 
an important trace element that may contribute significantly by mitigating the harmful effects 
in at least some of these diseases by augmenting the innate immune response and other mecha-
nisms, such as stabilizing the complex membrane and macromolecular structures. Nutrient, 
especially the micronutrient deficiencies in early childhood or at a later stage may result in great 
economic burden that can lower a country’s GDP [12]. Individualized nutrition and personal-
ized care have the potential of a positive impact on the healthcare sector with certain changes in 
the system [13]. Some of the required changes may involve largely policy issues and healthcare 
infrastructural changes [14], as well as economic changes [15, 16] to lower the cost of medication.
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2. Lifestyle diseases
Lifestyle factors such as bad eating habits, sedentary lifestyle, high-calorie diet and excessive 
alcohol intake increase the rate at which some or most chronic human diseases develop. Most 
of these diseases, which include cancer, diabetes and atherosclerosis, are a leading cause of 
death and pose great health and economic burden to the country [17]. Prevalence of diabe-
tes, in particular, continues to increase in the world. Diabetes is projected to be the seventh 
leading cause of death by the year 2030 [18]. Lifestyle changes such as personalized exercise 
(physical activity), personalized diet (nutrigenomics), and relaxation techniques (meditation 
and yoga) can help prevent or at least minimize the occurrence, as well as the prevalence, of 
these diseases [4].
Lifestyle changes and somewhat drug intervention have profound effect on the development 
and progression of chronic human diseases, including the disease progress, for example, from 
the prediabetes stage to diabetes, or even diabetes-associated complications. However, it is 
not clear who may or may not respond appropriately to a particular therapy. This is because 
individuals are different. Lifestyle changes like healthy eating and physical activity can do a lot 
of wonder in preventing chronic diseases when coupled with individual awareness to disease 
through genetic risk testing and other methods. Personalized or individualized nutrition holds 
great promise in the future and can be used to identify associations between genes, nutrients, 
and a disease so as to improve public health [19].
3. Diet-related chronic conditions
3.1. Diet and physical activity
Diet and (lack of) physical activity constitute some of the major contributory factors for 
the development of chronic illnesses, both noncommunicable and communicable, directly 
impacting the immune system of the body and metabolism. Diseases like tuberculosis fail to 
develop if an individual’s lifestyle is healthy with respect to diet and physical activity. In diet-
related complications such as obesity and T2D, a complex interplay of several factors includ-
ing both genetic predisposition and lifestyle of an individual has been reported [5, 19]. These 
factors can have serious devastating effects on health, as the appearance of one disease may 
increase the chance for another disease; for example, obesity alone may lead to an increase in 
T2D and CVD [20].
Diet-related diseases are generally chronic in nature and are often associated with age 
and type of diet (nutrition) [21]. Personalizing diet, i.e., increasing the nutritional qual-
ity of diet and genotyping (nutrigenomics), leads to achieving a better health [22]. Earlier, 
global guidelines on food, certain food groups, and other nutrient requirements of the 
population were recommended with the overall view of preventing or delaying the onset 
of diet-related diseases. Nowadays, with an increased understanding of genetic differences 
pertaining to nutritional requirements among individuals, scientists are making efforts to 
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categorize these guidelines based on inter-individual variation in dietary response result-
ing in a personalized diet, thus preventing chronic diet-related conditions [21]. Over the 
years, a number of clinicians and researchers have tried to demonstrate the importance of 
dietary modifications to achieve healthy and sustainable weight loss among overweight 
and obese individuals. However, these attempts could not yield positive results because 
of different metabolic roles of macromolecules such as the lipid, protein and carbohydrate 
in energy homeostasis and differences in metabolism. These molecules have a great effect 
on metabolism, appetite, and thermogenesis, which support the idea of considering the 
fuel value provided by each macromolecule separately. At times, even when considered 
separately, nature and kind of food constituents matter. For example, a diet which can 
reduce the risk of T2D and CVD is important for people who already have the disease. In 
this case, a fiber-rich or nonstarch polysaccharide diet, like whole grain, legumes, fruits and 
vegetables, is the most appropriate diet.
A sedentary lifestyle equally contributes to lifestyle diseases. It has been identified as a link 
between obesity, diabetes, metabolic syndrome, CVD, and death [23]. Physical inactivity is 
widely believed to be the primary cause of most preventable chronic conditions including 
diabetes, obesity and CVD. Therefore, physical activity may delay or prevent these and other 
chronic conditions [24]. Weight loss is recognized as one of the baseline strategies employed 
to deal with chronic inflammatory diseases like diabetes and CVD [25]. Obese individuals are 
overweight and prone to develop chronic inflammatory diseases. A holistic approach focus-
ing on changes in lifestyle including changes in diet to suit individual’s needs, and physical 
activity, together with compatible precision medicine and ridding of the bad habits is bound 
to have beneficial effect on the management and prevention of life-threatening diseases and 
associated complications.
3.2. Type 2 diabetes
Individuals with type 2 diabetes are often faced with insulin resistance (IR) challenge arising 
from an accumulation of triglycerides in adipose tissues. Studies have shown that weight loss 
can bring significant improvement in IR both in T2D and in those with impaired glucose toler-
ance [26]. Nonetheless, there is an array of inter-individual variations with regard to improve-
ment in insulin sensitivity and glycemia because of the individual response to changes in 
lifestyle factors such as the weight, diet and physical activity [5].
Increasing evidence has shown that single-nucleotide polymorphisms (SNPs) exist in diabe-
tes [27, 28], which gives a lot of scope for the treatment based on genetic characteristics of an 
individual. These genetic differences are considered as markers of diabetes risk as they can 
be used to predict the disease and also to determine diabetes onset [29]. Nearly 80 genetic 
loci are thought to influence genetic susceptibility to both types of diabetes. An integral part 
of diabetes management and self-management education, medical nutrition therapy (MNT), 
was designed to provide patients with specific care as well as guidelines on lifestyle changes 
an individual can make and maintain in order to improve health [30]. Once individuals’ basic 
nutritional requirements have been achieved, chances of developing disease are rare even for 
diabetics where nutrient supplementation may be an issue of concern [31].
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle116
3.3. Obesity
Management of obesity consists of the ability to lose weight either through exercise or person-
alized nutrition (non-pharmacological), or may involve the use of drugs. Due to individual 
genetic makeup and myriad of environmental factors, different individuals respond differ-
ently to exercise; some may even show resistance [32, 33]. Personalized exercise may help 
prevent unwanted individual response. In addition, identification of specific polymorphisms 
such as obesity-related SNPs may help find differences in dietary response to caloric restric-
tion. Personalized nutrition is, therefore, expected to play a role in determining the kind and 
nature of diet suitable for different individuals owing to the environmental and genetic dif-
ferences. Many of the diet-associated health burdens have been linked to SNPs, which is used 
to predict individual response to drugs in a population [34]. The most common examples 
of these polymorphisms are leptin/leptin receptor polymorphism (related to obesity gene), 
apolipoprotein (E and A1), which is related to CVD, and methylenetetrahydrofolate reductase 
(MTHR) related to folate metabolism [35].
3.4. Cardiovascular diseases
Cardiovascular diseases (CVDs) are a group of metabolic diseases arising from atherosclero-
sis [36]. CVDs account for the most common cause of morbidity and mortality in the world 
[36], with poorly controlled diabetes as one of the promoting factors. Newer technologies 
involving large-scale genotyping and sequencing have allowed for identification of heri-
table CVD risks which can be used in personalized treatment. Epigenetics and personalized 
attempts are increasingly proving beneficial and providing a new way to treat CVDs [37]. In 
the near future, it is hoped that the DNA sequence variants associated with CVD or which 
show association with the beneficial or adverse effects of medication and used to predict 
CVD risk may be identified and guide the decision of choosing the best medication and dose 
to individual patients.
3.5. Cancer
Much of the successful personalized treatments have been recorded in the area of oncology 
with many tumors and cancers being targeted with individualized regimens. Today, the 
world is witnessing a rapid progress in the upcoming field of personalized medicine with 
the emergence of genotyping industry for screening/testing, leading to an increased use of 
of precision medicines for cancer therapy. Many of these drugs are already available in the 
market and include kinase inhibitors [38]. Imatinib, lapatinib and erlotinib are some selective 
kinase inhibitors which are used to target anaplastic lymphoma [38].
3.6. Oral health and related diseases
Genomic information is increasing our understanding of oral health by providing an under-
standing of the disease etiology, thereby allowing easier diagnostic and a chance to take 
preventive measures to avoid the onset of oral diseases [39]. This is possible when genome 
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analysis and disease risk assessment is started at childhood, as it gives room for proper plan-
ning for individualized prevention and monitoring strategies. By doing so, oral health and 
related problems like dental caries, periodontitis, and oral cancers may be detected at the 
onset and treated.
3.7. Osteoporosis
Osteoporosis is a complicated preventable syndrome that affects millions of peoples, espe-
cially women, in the world. Several personalized medicine intervention procedures are being 
investigated to identify the individuals with a high tendency to the disease. For instance, 
FRAX(R) is an algorithm that enables physicians to calculate the tendency for an individual 
patient risk for osteoporosis for 10 years, as well as helps in the selection of appropriate drug 
taking into consideration the choice of the patient [40]. Prognosis, treatment, and prevention 
of fractures would be easier when gene variants associated with osteoporosis are identified, 
leading to a more personalized approach/therapy [41].
4. Conclusion
Personalized care is at the verge of a revolution in healthcare sector, with potential to revolu-
tionize the treatment, care and prevention of a number of debilitating life threatening diseases, 
some of which have been discussed in this chapter (Figure 1). When fully implemented, the 
treatment of patients can be individualized in strict accordance with their individual genetic 
make-up, rather than traditional “one-size-fits-all” pharmacology. A person’s lifestyle, which 
decides the overall well-being of an individual, is crucial while implementing the approach 
Figure 1. Diet-related conditions where personalized care can revolutionize the treatment, control and prevention of 
lifestyle diseases in human.
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of personalized care of patients suffering from long-term lifestyle debilitating and morbid 
diseases through individualized nutrition, personal hygiene/oral health, and individualized 
needs that may be combined with relaxation techniques, such as meditation and yoga.
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